| Market Cap | 2.38M |
| Revenue (ttm) | 350.00K |
| Net Income (ttm) | -26.95M |
| Shares Out | n/a |
| EPS (ttm) | -1.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,727,906 |
| Average Volume | 2,381,081 |
| Open | 0.0850 |
| Previous Close | 0.0850 |
| Day's Range | 0.0850 - 0.1040 |
| 52-Week Range | n/a |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | May 14, 2025 |
About Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m... [Read more]
Full Company ProfileFinancial Performance
In 2024, Palatin Technologies's revenue was $4.49 million, a decrease of -7.49% compared to the previous year's $4.85 million. Losses were -$29.74 million, 23.7% more than in 2023.
Financial StatementsNews
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory...
Palatin Technologies Announces Closing of Reduced Public Offering
Company Transitioned onto the OTC Pink CRANBURY, N.J. , May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing fir...
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company...